We are live on
!
Find out more
ACM
ADAR1 Capital Management Portfolio holdings
AUM
$1.7B
1-Year Est. Return
340.85%
This Fund
S&P 500
This Quarter
Est. Return
+8.25%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.7B
AUM Growth
+$337M
(+25%)
Cap. Flow
+$320M
Cap. Flow
% of AUM
18.81%
Top 10 Holdings %
Top 10 Hldgs %
39.64%
Holding
351
New
78
Increased
102
Reduced
60
Closed
41
Top Buys
| 1 |
Beam Therapeutics
BEAM
|
+$40.1M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$37.1M |
| 3 |
Denali Therapeutics
DNLI
|
+$36.2M |
| 4 |
Inspire Medical Systems
INSP
|
+$27.3M |
| 5 |
Vir Biotechnology
VIR
|
+$21.9M |
Top Sells
| 1 |
RNAM
Avidity Biosciences
RNAM
|
+$39.4M |
| 2 |
RAPT
RAPT Therapeutics
RAPT
|
+$17.3M |
| 3 |
CDTX
Cidara Therapeutics
CDTX
|
+$13.2M |
| 4 |
Fulcrum Therapeutics
FULC
|
+$10.4M |
| 5 |
Arbutus Biopharma
ABUS
|
+$9.98M |
Sector Composition
| 1 | Healthcare | 88.42% |
| 2 | Financials | 1.51% |
| 3 | Technology | 0.08% |
| 4 | Industrials | 0.08% |
| 5 | Materials | 0.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
276
Jasper Therapeutics
JSPR
$20.6M
| $123K | 0.01% |
140,000
| – | – |
|
|
NEUP
277
Neuphoria Therapeutics
NEUP
$19.4M
| $122K | 0.01% |
30,000
| – | – |
|
278
Milestone Pharmaceuticals
MIST
$154M
| $119K | 0.01% |
100,000
-100
| -0.1% | -$175 |
|
279
Arcturus Therapeutics
ARCT
$176M
| $116K | 0.01% |
+15,000
| New | +$109K |
|
280
MacroGenics
MGNX
$257M
| $116K | 0.01% |
+40,000
| New | +$85.3K |
|
281
C4 Therapeutics
CCCC
$391M
| $113K | 0.01% |
+43,000
| New | +$101K |
|
282
Recursion Pharmaceuticals
RXRX
$1.62B
| $107K | 0.01% |
35,000
| – | – |
|
283
Design Therapeutics
DSGN
$768M
| $106K | 0.01% |
+10,000
| New | +$101K |
|
284
Gossamer Bio
GOSS
$80.3M
| $94.5K | 0.01% |
287,531
+75,000
| +35% | +$118K |
|
285
Immix Biopharma
IMMX
$715M
| $91.1K | 0.01% |
10,000
-40,000
| -80% | -$294K |
|
286
CALL
Solidion Technology
STI
$53.5M
| $85.2K | 0.01% |
13,500
| – | – |
|
|
LITS
287
Lite Strategy Inc
LITS
$33.2M
| $78.1K | ﹤0.01% |
67,292
| – | – |
|
288
Veru
VERU
$36.9M
| $77.3K | ﹤0.01% |
35,000
| – | – |
|
|
KYNB
289
Kyntra Bio
KYNB
$30.2M
| $71K | ﹤0.01% |
10,469
| – | – |
|
290
Clover Health Investments
CLOV
$2.35B
| $70.4K | ﹤0.01% |
40,000
-8,300
| -17% | -$18K |
|
291
Biomea Fusion
BMEA
$90.4M
| $66.4K | ﹤0.01% |
43,420
| – | – |
|
292
Neumora Therapeutics
NMRA
$296M
| $64.5K | ﹤0.01% |
33,100
-17,500
| -35% | -$45.3K |
|
293
Organon & Co
OGN
$3.55B
| $59.9K | ﹤0.01% |
10,000
-25,000
| -71% | -$188K |
|
|
ESPR
294
DELISTED
Esperion Therapeutics
ESPR
| $58.6K | ﹤0.01% |
+21,400
| New | +$67.7K |
|
|
MREO
295
Mereo BioPharma
MREO
$52M
| $49.5K | ﹤0.01% |
150,000
| – | – |
|
296
AN2 Therapeutics
ANTX
$169M
| $47.4K | ﹤0.01% |
+13,861
| New | +$28.6K |
|
|
ASPCR
297
A SPAC III Acquisition Corp Right
ASPCR
| $42.4K | ﹤0.01% |
215,000
| – | – |
|
298
Aquestive Therapeutics
AQST
$499M
| $41.5K | ﹤0.01% |
+10,000
| New | +$40.6K |
|
|
ATYR
299
aTyr Pharma
ATYR
$49.2M
| $39.5K | ﹤0.01% |
50,685
| – | – |
|
300
BioAtla
BCAB
$6.51M
| $36.7K | ﹤0.01% |
4,562
+900
| +25% | +$10.5K |
|
Similar funds
RSCM
AAM
SGI
WAS
BCM
SWM
TCM
ISS